All In MedTech

Device Trial Radar · NCT04253431

The Characteristics of Different Personal Lancets on Blood Volume and Perceived Pain in Patients With Diabetes Mellitus

A Single-blind, Randomized, Single-centre Study to Investigate the Characteristics of Different Personal Lancets on Blood Volume and Perceived Pain in Patients With Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Feb 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Aug 2013

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Lead sponsor
HTL-Strefa S.A.Not on our public-company list
Sponsor type
Industry
First posted
Feb 5, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized single-blind study with the use of different lancing devices equipped with personal lancets to determine and to compare the amount of capillary blood volume and perceived pain after a single lancing of the fingertip.

Conditions

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Interventions

  • Droplet lancing device (HTL-Strefa S.A.)Device

  • Microlet 2 lancing device (Bayer)Device

  • OneTouch Delicia lancing device (LifeScan)Device

  • ReliOn lancing device (ReliOn)Device

  • Accu-Chek Softclix lancing device (Roche)Device

  • BGStar lancing device (Sanofi Aventis)Device

  • Ultra-Fine 33G lancets (BD)Device

  • Droplet 33G lancets (HTL-Strefa S.A.)Device

  • OneTouch Delicia Extra Fine 33G lancets (LifeScan)Device

  • HaemoFine 33G lancets (HTL-Strefa S.A.)Device

  • Softclix 28 G lancets (Roche)Device

  • ReliOn Ultra-Thin Plus 33G lancets (ReliOn)Device

  • GlucoJect Dual S lancing device (Menarini)Device

  • Microlet 28G lancets (Bayer)Device

  • BGStar Ultra-Thin 33G lancets (Sanofi Aventis)Device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Volume (uL) of blood in the capillary tubeTime frame: The blood from the puncture site was collected to the capillaries for 30 seconds, and afterwards amount of the blood was measured using a calibrated ruler

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.